Janssen Collaborates with BioMedX in Autoimmunity and Drug Delivery Research

News
Article

BioMed X Institute and Janssen Research & Development to start two new research programs in the field of autoimmune diseases and drug delivery.

BioMed X, an independent German research institute, announced on August 2, 2021 the start of two new research projects with Janssen Research & Development, which is one of the Janssen Pharmaceutical Companies of Johnson & Johnson (J&J). Both collaborations were facilitated by J&J Innovation.

The aim of the first research group, Protective Tissue Factors in Autoimmune Diseases (PTA), is to develop new approaches to combat chronic inflammatory diseases and identify protective factors in the tissue microenvironment of patients with auto-inflammatory diseases. The overall goal, therefore, would be discovering and validating novel drug targets in these diseases.

“We aim to develop a 3D human joint-in-a-dish platform that closely mimics the inflamed joints of patients with rheumatoid arthritis utilizing diverse methodologies including single-cell omics, gene-editing, bio-scaffold manufacturing, and stem to adult joint cell differentiation,” said Mojca Frank Bertoncelj, the new group leader of team PTA, in a press release. “This innovative platform will enable high-throughput testing and discovery of novel joint-protective therapeutics.”

The second research group, Translocation of Complex Macromolecules Across the Intestinal Epithelial Barrier (TMI), aims to discover novel transport mechanisms in the human intestinal tract that could be used for oral delivery of various macromolar therapeutic modalities.

“Our mission is to characterize the human intestinal epithelial barrier and thereby gain insights into how macromolecular therapeutics may be orally delivered,” said Dr. Kyungbo Kim, new group leader of team TMI, in the release. “The biology of the barrier will be explored at the cellular and molecular level.”

Source: BioMed X

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content